Intro: The Exodus from XRemember when Twitter was a chaotic but lovable place where you could scream into the void, live-tweet your bad decisions, and occasionally witness the downfall of a celebrity ...

Some might argue that it's too late for investors to get in on Eli Lilly, while others could feel that its work in the diabetes and obesity markets still makes it an attractive long-term option.

1,2 The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly and Company (NYSE: LLY). Launched in 2022, the ...

FDA-approved medicines," Eli Lilly CEO Dave Ricks said in a statement Wednesday. The company began building out capacity as demand for its blockbuster GLP-1 products — Mounjaro for diabetes and ...

president of Eli Lilly diabetes and obesity, in an interview. Medicare beneficiaries are also not eligible for Eli Lilly's savings card programs for Zepbound. Jonsson said "in an ideal world," the ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Eli Lilly said it will invest at least $27 billion to build four new manufacturing sites in the U.S. as demand for its weight loss and diabetes injections soars and the company develops new drugs.

Eli Lilly and Co. Wednesday ... tech mecca in Lebanon, Indiana. Lilly has said the company expects to increase production for its blockbuster weight loss and diabetes drugs at the 9,000 acre ...